FDA
-
-
-
-
-
-
-
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
-
-
-
-
-
-
-
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in P
-
-
-
-
-
-
-
Longeveron to Present at BIO International Convention 2026
-
-
-
-
-
-
-
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
-
-
-
-
-
-
-
Longeveron secures $30 million private placement for clinical trials
-
-
-
-
-
-
-
Longeveron receives Japan patent for stem cell potency testing methods
-
-
-
-
-
-
-
Longeveron executives to speak at cardiovascular clinical trials forum
-
331,401 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

